Skip to main content
MediPharm Labs Corp. logo

MediPharm Labs Corp. — Investor Relations & Filings

Ticker · LABS LEI · 875500SIGS9KXW34K754 TSX Manufacturing
Filings indexed 274 across all filing types
Latest filing 2024-12-24 Regulatory Filings
Country CA Canada
Listing TSX LABS

About MediPharm Labs Corp.

https://medipharmlabs.com/

MediPharm Labs Corp. is a full-service pharmaceutical company specializing in the development, formulation, processing, packaging, and distribution of precision-based, advanced cannabinoid products. Operating from Good Manufacturing Practices (GMP) certified facilities, the company focuses on producing pharma-quality cannabis Active Pharmaceutical Ingredients (API), concentrates, and derivative products. Utilizing strict manufacturing standards and ISO standard cleanrooms, MediPharm Labs ensures its offerings are pure, trusted, and precisely dosable for patients and consumers. Services include wholesale and white label platforms for domestic and international clients. The company holds a Pharmaceutical Drug Establishment License, enabling the manufacture of pharmaceutical drugs containing cannabis.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings Classification · 1% confidence The document is a Canadian Form 51-102F3 “Material Change Report” detailing a corporate sale transaction. It is a regulatory disclosure under NI 51-102, not an earnings release, management discussion, proxy, or dividend notice. Although it describes a transaction (share sale of a subsidiary), it is a regulatory filing of a material change rather than a formal M&A tender or proxy. It does not fit any more specific category, so it defaults to the general Regulatory Filings category (RNS).
2024-12-24 English
Other material contracts - English.pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 certification by the CEO of SLAM Exploration Ltd. confirming review and fair presentation of the interim financial report and MD&A for the period ended October 31, 2024. It is a regulatory certification form under Canadian securities rules (NI 52-109) rather than the interim financial report itself, an MD&A, or an earnings release. It does not represent a substantive financial report nor an announcement that a report is available, but is a standalone regulatory filing. There is no specific category for certification forms in our taxonomy, so it falls into the fallback category of Regulatory Filings (RNS).
2024-12-20 English
News release - English.pdf
Regulatory Filings
2024-11-14 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2024-11-14 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2024-11-14 English
Interim MD&A - English.pdf
Regulatory Filings
2024-11-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.